Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2009, vol. 18, nr 1, January-February, p. 25–31

Publication type: original article

Language: English

The Prognostic Value of Cyclin D1 Expression in Resected Non−Small−Cell Lung Cancer of Stages I–IIIA – Preliminary Report

Próba oceny prognostycznego znaczenia ekspresji cykliny D1 w operowanym niedrobnokomórkowym raku płuca w stadium I–IIIA – doniesienie wstępne

Monika Kosacka1,, Irena Porębska1,, Renata Jankowska1,

1 Chair and Department of Pulmonology and Lung Cancer, Wroclaw Medical University, Poland

Abstract

Background. Lung cancer is the leading cause of cancer death in the majority of developed counties and in Poland. Cyclin D1 regulates the G1−to−S phase transition and its gene is located on chromosome 11q13.
Objectives. The aim of this study was to evaluate the prognostic significance of cyclin D1 expression in primary resected stage I–IIIA non−small−cell lung cancer (NSCLC).
Material and Methods. The expression of cyclin D1 in paraffin−embedded tumor tissue from 71 patients (53 men and 18 women, mean age: 59.27 ± 8.50 years) was measured using a monoclonal antibody to cyclin D1 (NCL−L−Cyclin D1−Gm clone P2D11F11, Novocastra).
Results. Forty−one (58%) tumor tissue specimens were positive for cyclin D1. Two distinct patterns of staining were observed, but cytoplasmic staining were found in the majority of cases. The prognostic value of cyclin D1 expression was analyzed in all the examined patients and separately in patients with squamous cell lung cancer and adenocarcinoma and for each stage, but only in stage II was there negative correlation between cyclin D1 expression and survival.
Conclusion. Expression of cyclin D1 could be negative prognostic factor in some patients with resected nonsmall−cell lung cancer.

Streszczenie

Wprowadzenie. Rak płuca jest główną przyczyną zgonów z powodu chorób nowotworowych w większości rozwiniętych krajów i w Polsce. Cyklina D1 bierze udział w regulacji fazy G1−S cyklu komórkowego, a jej gen jest umiejscowiony na chromosomie 11q13.
Cel pracy. Próba oceny znaczenia prognostycznego ekspresji cykliny D1 w operowanym niedrobnokomórkowym raku płuca – stadium I–IIIA.
Materiał i metody. Metodą immunohistochemiczną przeprowadzono badanie preparatów guza utrwalonych w parafinie pobranego od 71 pacjentów (w tym 53 mężczyzn i 18 kobiet, średni wiek 59,27 + 8,50). Użyto przeciwciała monoklonalnego przeciw cyklinie D1: NCL−L−Cyclin D1−Gm clone P2D11F11 novocastra.
Wyniki. W 51 preparatach (58%) stwierdzono ekspresję cykliny D1, w większości przypadków była to reakcja cytoplazmatyczna. Analizowano prognostyczne znaczenie ekspresji cykliny D1 w całej badanej grupie, a następnie u chorych na raka płaskonabłonkowego i na gruczolakoraka, a także w poszczególnych stadiach zaawansowania. Stwierdzono jedynie ujemną korelację między ekspresją cykliny D1 a przeżyciem w stadium II. Wnioski: Ekspresja cykliny D1 może być niekorzystnym czynnikiem rokowniczym u części chorych leczonych operacyjnie z powodu niedrobnokomórkowego raka płuca.

Key words

cyclin D1, non−small−cell lung cancer, squamous cell lung cancer, adenocarcinoma, prognostic factor

Słowa kluczowe

cyklina D1, niedrobnokomórkowy rak płuca, rak płaskonabłonkowy, gruczolakorak, czynnik prognostyczny

References (20)

  1. Mountain CF: The international system for staging lung cancer. Semin Surg Oncol 2000, 18(2), 106–115.
  2. Skuladottir H, Olsen JH: Epidemiology of lung cancer. In: Spiro S.G (ed.). Lung cancer, ERS Journals 2001, Ltd., Sheffield, 1–12.
  3. Survival of Cancer Patients in Europe: the Eurocare−3 study. Ann Oncol 2003, 14, Supplement. http://eurocare.it/
  4. Welch HG, Schwartz LM, Woloshin S: Are increasing 5−year survival rates evidence of success against cancer? Jama 2000, 283, 2975–2978.
  5. Zhu CQ, Shih W, Ling CH, Tsao MS: Immunohistochemical markers of prognosis in non−small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006, 59 (8), 790–800.
  6. Mac Lachlan TK, Sang N, Giordano A: Cyclins, cyclin−dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995, 5(2), 127–156.
  7. Caputi M, Groeger AM, Esposito V, Dean C, De Luca A, Pacilio C, Muller MR, Giordano GG, Baldia F, Wolner E, Giordano A: Prognostic role of cyclin D1 in lung cancer. Relationship to proliferating cell nuclear antigen. Am J Respir Cell Mol Biol 1999, 20, 746–750.
  8. Dworakowska D: Rola białka p53, pRB, p21WAF1/CIP1, PCNA, mdm2 oraz cykliny D1 w regulacji cyklu komórkowego oraz apoptozy. Onkol Pol 2005, 8, 4, 223–228.
  9. Aaltomaa S, Lipponen P, Ala−Opas M, Eskelinen M, Syrjanen K, Kosma VM: Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Br J Cancer 1999, 80(12), 2001–2007.
  10. Itami A, Shimada Y, Watanabe G, Imamura M: Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology 1999, 57(4), 311–317.
  11. Sato Y, Itoh F, Hareyama M, Satoh M, Hinoda Y, Seto M, Ueda R, Imai K: Association of cyclin D1 expression with factors correlated with tumor progression in human hepatocellular carcinoma. J Gastroenterol 1999, 34 (4), 486–493.
  12. Ayeda AK, Adesina A: Prognostic significance of cyclin D1 expression in resected stage I, II non−small cell lung cancer in Arabs. Interact CardioVasc Thorac Surg 2006, 5, 47–51.
  13. Nguyen VN, Mirejovský P, Mirejovský T, Melínová L, Mandys V: Expression of cyclin D1, Ki−67 and PCNA in non−small cell lung cancer: prognostic significance and comparison with p53 and bcl−2. Acta Histochem. 2000 Aug, 102(3), 323–338.
  14. Betticher DC, Heighway J, Hasleton PS, Altermatt HJ, Ryder WD, Cerny T, Thatcher N: Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non−small−cell lung cancer. Br J Cancer. 1996 Feb, 73(3), 294–300.
  15. Radović S, Babić M, Dorić M, Hukić A, Kuskunović S, Hadzismajlović A, Serdarević F: Non−small cell lung carcinoma: cyclin D1, bcl−2, p53, Ki−67 and HER−2 proteins expression in resected tumors. Bosn J Basic Med Sci 2007 7(3), 205–211.
  16. Mishina T, Dosaka−Akita H, Kinoshita I, Hommura F, Morikawa T, Katoh H, Kawasaki Y: Cyclin D1 expression in non−small−cell lung cancer: its association with altered p53 expression, cell proliferation and clinical outcome. Br J Cancer 1999, 80(8), 1289–1295.
  17. Volm M, Koomägi R: Association of cyclin D1 expression in lung cancer and the smoking habits of patients. Cancer Lett. 1999, 141(1–2), 147–150.
  18. Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar−Sagi D, Roussel MF, Sherr CJ: Overexpression of mouse D−type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993, 7(8), 1559–1571.
  19. Gautschi O, Hugli B, Ziegler A, Bigosch C, Bowers NL, RatschillerD, Jermann M, Stahel RA, HeighwayJ, Betticher DC: CyclinD1 (CCND1) A870G gene polymorphism modulates smoking−induced lung cancer risk and response to platinum−based chemotherapy in non−small cell lung cancer (NSCLC) patients. Lung Cancer 2006, 51(3), 303–311.
  20. Takahashi−Yanaga F, Sasaguri T: GSK−3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal 2008, 20(4), 581–589.
© Wroclaw Medical University